Di Monda Vincenzo, Nicolodi Maria, Aloisio Antonina, Del Bianco Pierluigi, Fonzari Marco, Grazioli Irene, Uslenghi Carla, Vecchiet Leonardo, Sicuteri Federigo
Neurology Division I, Spedali Civili di Brescia, Italy.
Headache. 2003 Sep;43(8):835-44. doi: 10.1046/j.1526-4610.2003.03161.x.
To compare the efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine suppositories with sumatriptan suppositories in the treatment of 2 consecutive migraine attacks of moderate or severe intensity in a multicenter, randomized, crossover study.
A fixed combination of indomethacin, prochlorperazine, and caffeine is the most commonly used drug for the acute treatment of migraine in Italy. No studies have been published comparing the efficacy of this combination with sumatriptan, the most widely prescribed of the triptans.
One hundred twelve patients with migraine with or without aura according to the diagnostic criteria of the International Headache Society were randomized to treat 2 migraine attacks with a fixed combination of indomethacin, prochlorperazine, and caffeine and 2 migraine attacks with sumatriptan. Both drugs were rectally administered in a single dose for each attack. Patients were asked to take study medication as soon as possible at the onset of a headache.
Of the 112 patients, 88 were compliant to the protocol. More attacks became pain-free at 2 hours postdose (primary end point) on the combination than on sumatriptan (49% versus 34%; P<.01), while there was no difference in the relief of headache at 2 hours postdose (71% versus 65%). The combination was statistically superior to sumatriptan in the time to a pain-free response (a higher percentage of attacks became pain-free from 0.5 hours postdose to 5 hours postdose), in alleviation of nausea, and in a sustained pain-free response (pain-free at 2 hours postdose with no use of rescue medication or relapses within 48 hours). Moreover, a significant consistent response was achieved for the combination compared with sumatriptan across (higher percentage of patients pain-free at 2 hours postdose in the first, second, third, and fourth treated attack) and within patients (pain-free in 2 of 2 treated attacks in 35% of patients taking the combination and 20% of patients on sumatriptan). Both drugs were well-tolerated.
This study, analyzed according to the more recent guidelines for controlled trials in migraine, showed that a fixed combination of indomethacin, prochlorperazine, and caffeine is significantly more effective than sumatriptan in the acute treatment of migraine attacks. It is notable that the combination is less expensive than sumatriptan per unit dose.
在一项多中心、随机、交叉研究中,比较吲哚美辛、异丙嗪和咖啡因栓剂固定组合与舒马曲坦栓剂治疗2次连续中度或重度偏头痛发作的疗效。
在意大利,吲哚美辛、异丙嗪和咖啡因的固定组合是偏头痛急性治疗中最常用的药物。尚未发表将该组合与最广泛处方的曲坦类药物舒马曲坦的疗效进行比较的研究。
112例符合国际头痛协会诊断标准的有或无先兆偏头痛患者被随机分配,用吲哚美辛、异丙嗪和咖啡因固定组合治疗2次偏头痛发作,并用舒马曲坦治疗2次偏头痛发作。每次发作均采用直肠单剂量给药。要求患者在头痛发作时尽快服用研究药物。
112例患者中,88例符合方案。与舒马曲坦相比,组合用药后2小时(主要终点)无痛发作更多(49%对34%;P<0.01),而用药后2小时头痛缓解情况无差异(71%对65%)。在无痛反应时间(从用药后0.5小时到5小时无痛发作百分比更高)、缓解恶心以及持续无痛反应(用药后2小时无痛且48小时内未使用急救药物或复发)方面,组合用药在统计学上优于舒马曲坦。此外,与舒马曲坦相比,组合用药在各次发作间(第一次、第二次、第三次和第四次治疗发作中用药后2小时无痛患者百分比更高)以及患者个体内(服用组合用药的患者中35%在2次治疗发作中有2次无痛,服用舒马曲坦的患者中为20%)均取得了显著一致的反应。两种药物耐受性均良好。
根据偏头痛对照试验的最新指南进行分析,本研究表明,吲哚美辛、异丙嗪和咖啡因固定组合在偏头痛发作的急性治疗中比舒马曲坦显著更有效。值得注意的是,该组合每单位剂量比舒马曲坦便宜。